WuXi XDC Cayman Inc
HKEX:2268
Intrinsic Value
WuXi XDC Cayman Inc is a CN-based company operating in Life Sciences Tools & Services industry. [ Read More ]
The intrinsic value of one WuXi XDC Cayman Inc stock under the Base Case scenario is 14.13 HKD. Compared to the current market price of 18.52 HKD, WuXi XDC Cayman Inc is Overvalued by 24%.
Valuation Backtest
WuXi XDC Cayman Inc
Run backtest to discover the historical profit from buying and selling WuXi XDC Cayman Inc stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
WuXi XDC Cayman Inc
WuXi XDC Cayman Inc
Earnings Waterfall
WuXi XDC Cayman Inc
|
Revenue
|
990.4m
CNY
|
|
Cost of Revenue
|
-729.3m
CNY
|
|
Gross Profit
|
261.1m
CNY
|
|
Operating Expenses
|
-113.3m
CNY
|
|
Operating Income
|
147.8m
CNY
|
|
Other Expenses
|
7.9m
CNY
|
|
Net Income
|
155.7m
CNY
|
Free Cash Flow Analysis
WuXi XDC Cayman Inc
Profitability Score
Profitability Due Diligence
WuXi XDC Cayman Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
Score
WuXi XDC Cayman Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
WuXi XDC Cayman Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Score
WuXi XDC Cayman Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
WuXi XDC Cayman Inc
According to Wall Street analysts, the average 1-year price target for WuXi XDC Cayman Inc is 31.04 HKD with a low forecast of 18.18 HKD and a high forecast of 44.1 HKD.
Shareholder Return
Price
WuXi XDC Cayman Inc
| Average Annual Return | 1 047.54% |
| Standard Deviation of Annual Returns |
N/A
|
| Max Drawdown | -90% |
| Market Capitalization | 22.3B HKD |
| Shares Outstanding | 1 197 604 500 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
WuXi XDC Cayman Inc is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Wuxi, Jiangsu and currently employs 1,113 full-time employees. The company went IPO on 2023-11-17. WuXi XDC Cayman Inc is a holding company primarily engaged in the provision of contract research, development and manufacturing services (CRDMO) for antibody drug conjugates (ADCs) and a wider range of bioconjugate drugs. The firm conducts its businesses through two segments. Research Services on Fee-for-service(FFS) Basis segment providing research services to its customers through FFS contracts. The Research Services on Full-time-equivalent(FTE) Basis segment providing a project team of employees dedicated to the customer's studies for a specific period of time. Based on biopharmaceuticals and small molecule drugs, the Company also provides comprehensive cross-domain services, covering the discovery, process development and good manufacturing practice (GMP) production of bioconjugated drugs, linkers and payloads. The firm conducts its business in domestic and foreign markets.
Contact
IPO
Employees
Officers
The intrinsic value of one WuXi XDC Cayman Inc stock under the Base Case scenario is 14.13 HKD.
Compared to the current market price of 18.52 HKD, WuXi XDC Cayman Inc is Overvalued by 24%.
You don't have any saved screeners yet
